Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration
- PMID: 3382589
- PMCID: PMC1387808
- DOI: 10.1111/j.1365-2125.1988.tb03330.x
Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration
Abstract
1. In an open cross-over trial, plasma concentrations of midazolam were measured in eight healthy male volunteers following administration of 0.3 mg kg-1 body weight given by the rectal and intravenous routes. 2. Maximum plasma concentrations of 92-156 ng ml-1 (mean 118 ng ml-1) were recorded from 20 to 50 min (mean 31 min) after rectal application. The rectal bioavailability was 40-65% (mean 52%) and the terminal half-life was 114-305 min (mean 161 min). 3. A substantial first-pass hepatic effect was observed following rectal administration. 4. No systemic or local intolerance was noted. 5. In conclusion, the rectal route of administration provides a rapid and reliable absorption of midazolam.
Similar articles
-
Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.Br J Clin Pharmacol. 2002 May;53(5):501-7. doi: 10.1046/j.1365-2125.2002.01588.x. Br J Clin Pharmacol. 2002. PMID: 11994056 Free PMC article. Clinical Trial.
-
Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.J Vet Pharmacol Ther. 1992 Dec;15(4):343-50. doi: 10.1111/j.1365-2885.1992.tb01026.x. J Vet Pharmacol Ther. 1992. PMID: 1487833
-
[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children].Anaesthesist. 1989 Dec;38(12):658-63. Anaesthesist. 1989. PMID: 2619028 German.
-
Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs.Clin Pharmacokinet. 1991 Jul;21(1):11-26. doi: 10.2165/00003088-199121010-00002. Clin Pharmacokinet. 1991. PMID: 1717195 Review.
-
The use of isotopes in the determination of absolute bioavailability of drugs in humans.Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):419-27. doi: 10.1517/17425255.2.3.419. Expert Opin Drug Metab Toxicol. 2006. PMID: 16863443 Review.
Cited by
-
Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.Br J Clin Pharmacol. 2002 May;53(5):501-7. doi: 10.1046/j.1365-2125.2002.01588.x. Br J Clin Pharmacol. 2002. PMID: 11994056 Free PMC article. Clinical Trial.
-
Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models.Pharmaceutics. 2025 Feb 7;17(2):214. doi: 10.3390/pharmaceutics17020214. Pharmaceutics. 2025. PMID: 40006581 Free PMC article.
-
Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Br J Clin Pharmacol. 2017 Apr;83(4):777-790. doi: 10.1111/bcp.13160. Epub 2016 Dec 2. Br J Clin Pharmacol. 2017. PMID: 27767204 Free PMC article.
-
Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.Br J Clin Pharmacol. 2002 Oct;54(4):357-62. doi: 10.1046/j.1365-2125.2002.01665.x. Br J Clin Pharmacol. 2002. PMID: 12392582 Free PMC article. Clinical Trial.
-
Rectal administration of midazolam versus diazepam for preanesthetic sedation in children.Anesth Prog. 1990 Jan-Feb;37(1):29-31. Anesth Prog. 1990. PMID: 2077983 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical